NasdaqGS - Delayed Quote • USD
Edgewise Therapeutics, Inc. (EWTX)
At close: 4:00 PM EDT
After hours: 4:02 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.35 | -0.36 | -1.55 | -2.01 |
| Low Estimate | -0.41 | -0.43 | -2.2 | -2.79 |
| High Estimate | -0.31 | -0.32 | -1.32 | -1.41 |
| Year Ago EPS | -0.34 | -0.41 | -1.58 | -1.55 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.4 | -0.4 | -0.43 | -0.39 |
| EPS Actual | -0.34 | -0.41 | -0.47 | -0.33 |
| Difference | 0.06 | -0.01 | -0.04 | 0.06 |
| Surprise % | 15.00% | -2.50% | -9.30% | 15.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.35 | -0.36 | -1.55 | -2.01 |
| 7 Days Ago | -0.35 | -0.36 | -1.55 | -2.01 |
| 30 Days Ago | -0.38 | -0.4 | -1.72 | -2.05 |
| 60 Days Ago | -0.38 | -0.4 | -1.72 | -2.05 |
| 90 Days Ago | -0.37 | -0.4 | -1.68 | -1.85 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 4 | 4 | 4 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | EWTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -2.90% | -- | -- | 7.90% |
| Next Qtr. | 12.20% | -- | -- | 10.20% |
| Current Year | 1.90% | -- | -- | 4.80% |
| Next Year | -29.70% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 4/22/2024 |
| Maintains | Truist Securities: Buy to Buy | 4/17/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 4/16/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 3/12/2024 |
| Initiated | Piper Sandler: Overweight | 3/7/2024 |
| Maintains | Wedbush: Outperform to Outperform | 11/10/2023 |
Related Tickers
AVTE Aerovate Therapeutics, Inc.
16.07
-5.97%
CGEM Cullinan Therapeutics, Inc.
23.03
-4.56%
KYMR Kymera Therapeutics, Inc.
33.53
-1.53%
IDYA IDEAYA Biosciences, Inc.
37.53
-0.48%
ATXS Astria Therapeutics, Inc.
9.05
+0.33%
APGE Apogee Therapeutics, Inc.
47.86
-0.35%
CGON CG Oncology, Inc.
32.43
-0.86%
SWTX SpringWorks Therapeutics, Inc.
42.31
-0.17%
CRNX Crinetics Pharmaceuticals, Inc.
46.86
-1.29%
SLRN Acelyrin, Inc.
4.0500
-1.94%